Mala Dharmalingam
Overview
Explore the profile of Mala Dharmalingam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
488
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shamanna P, Joshi S, Dharmalingam M, Vadavi A, Keshavamurthy A, Shah L, et al.
JACC Adv
. 2024 Oct;
3(9):101172.
PMID: 39372467
Background: Digital twin (DT)-guided lifestyle changes induce type 2 diabetes (T2D) remission but effects on hypertension (HTN) in this population are unknown. Objectives: The purpose of this study was to...
2.
Boyareddy H, Kalra P, Dharmalingam M
Indian J Endocrinol Metab
. 2024 Oct;
28(4):413-416.
PMID: 39371663
Introduction: Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disorder requiring treatment with steroids. Both over and under-treatment can have an impact on growth outcomes. Aims: The aim of...
3.
Ali M, Singh K, Kondal D, Devarajan R, Patel S, Menon V, et al.
PLoS Med
. 2024 Jun;
21(6):e1004335.
PMID: 38829880
Background: Diabetes control is poor globally and leads to burdensome microvascular and macrovascular complications. We aimed to assess post hoc between-group differences in sustained risk factor control and macrovascular and...
4.
Dharmalingam M, Sharma S, Prakash V, Maiti A, Kumar R, Murthy L, et al.
Cureus
. 2024 May;
16(4):e58115.
PMID: 38738005
Background Type 2 diabetes mellitus (T2DM) patients commonly undergo metformin monotherapy. This study aims to compare the efficacy, safety, and tolerability of combination therapy of dapagliflozin plus linagliptin versus dapagliflozin...
5.
Lu C, Dharmalingam M, P R M, Y P G, Selvan C, Kalra P
Cureus
. 2024 Feb;
16(1):e52610.
PMID: 38374858
Background: Subclinical thyrotoxicosis (SCH) is characterized by normal serum thyroid hormone levels and low thyrotropin levels. The impact of this condition on the skeletal system may vary depending on its...
6.
Bobba R, Kalra P, Dharmalingam M
Indian J Endocrinol Metab
. 2024 Feb;
27(6):486-491.
PMID: 38371188
Introduction: Gender affirming hormone therapy (GAHT) is the mainstay treatment in transitioning individuals and has positive physical and psychological effects. Among the things to monitor in transgender patients on long-term...
7.
Kumbar L, Kiran B, Dharmalingam M, Kalra P
Indian J Endocrinol Metab
. 2023 Oct;
27(4):330-334.
PMID: 37867987
Background: Fibroblast growth factor (FGF21) is a metabolic regulator whose role in humans is unidentified. FGF21 has generated a lot of potential of becoming a therapeutic agent for the management...
8.
Joshi S, Shamanna P, Dharmalingam M, Vadavi A, Keshavamurthy A, Shah L, et al.
Endocr Pract
. 2023 Oct;
29(12):960-970.
PMID: 37778441
Objective: Postprandial hyperglycemia drives insulin resistance and inflammation, leading to metabolic dysfunction-associated fatty liver disease (MAFLD). Prediction of postprandial glycemic responses by digital twin (DT) technology can fashion a personalized...
9.
Mithal A, Ramachandran A, Bhattacharyya A, Chadha M, Dharmalingam M, Majumder A, et al.
J Assoc Physicians India
. 2023 Aug;
71(8):11-12.
PMID: 37651251
Introduction: The burden of type 2 diabetes mellitus (T2DM) is raising dramatically both internationally and in India. It is often observed that multiple therapies or combinations of different drugs are...
10.
Joshi S, Chowdhury S, Dharmalingam M, Bhandari S, Deshmukh V, Cruz M, et al.
J Assoc Physicians India
. 2023 Jul;
71(7):45-51.
PMID: 37449690
Aims: We aimed to assess the prevalence of pancreatic exocrine insufficiency (PEI) in Indian patients with type 1 diabetes (T1D) or type 2 diabetes (T2D) using a unique diagnostic criterion....